戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ic) and those that did not develop LIDs (non-dyskinetic).
2 in parkinsonian mice that have been rendered dyskinetic.
3 be good apomorphine antagonists but all were dyskinetic.
4 ts N-2-(2-hydroxyethoxy)ethyl analogue 3 was dyskinetic.
5 zepines, 2 was not dyskinetic whereas 2a was dyskinetic.
6 m and a reduction in SN of both unprimed and dyskinetic 6-hydroxydopamine rats, consistent with oppos
7 equency significantly increased in ON L-DOPA dyskinetic 6-hydroxydopamine-lesioned rats, suggesting t
8 lidum does not separate antiparkinsonian and dyskinetic actions implies that they are closely related
9 size, percentage of the LV that was akinetic/dyskinetic (%AD), and LV shape index.
10  size (maximum dimension, 10 to 66 mm), were dyskinetic/akinetic with thin rims, and were associated
11  In the 'OFF' state withdrawn from levodopa, dyskinetic and non-dyskinetic patients had similar level
12                                         When dyskinetic and nondyskinetic patients were studied with
13                                              Dyskinetic and nondyskinetic PD patients were studied us
14 DOPA and monoaminergic pathways in brains of dyskinetic and nondyskinetic primates.
15 treated rats into those that developed LIDs (dyskinetic) and those that did not develop LIDs (non-dys
16  stress, with normal, hypokinetic, akinetic, dyskinetic, and aneurysmal segments scoring 0 to 4, resp
17 entially expressed between highly and weakly dyskinetic animals after treatment with L-DOPA.
18 methyldopa, in all measured brain regions of dyskinetic animals and increases in dopamine and metabol
19 y contact(i.e., multisynaptic spines) in the dyskinetic animals compared with the 6-hydroxydopamine-t
20                   To test motor function and dyskinetic anomalies, we examined cylinder behaviour and
21 between 15% and 40%, and dilated akinetic or dyskinetic anterior-apical wall without the need to be r
22 area r=-0.51, P<0.0001; RVOT displacement of dyskinetic area r=-0.49, P<0.0001; and RVOT late gadolin
23 VOT ejection fraction r=0.64, P<0.0001; RVOT dyskinetic area r=-0.51, P<0.0001; RVOT displacement of
24 l extent of dyskinetic area, displacement of dyskinetic area, and score of extent of late gadolinium
25 gmental ejection fraction, spatial extent of dyskinetic area, displacement of dyskinetic area, and sc
26                             Previously, only dyskinetic areas were treated by operation.
27 st, children with quadriplegic and mixed CP (dyskinetic, athetoid, hypotonic, and ataxic) more often
28  the human disorder PNKD, animals experience dyskinetic attacks in response to caffeine or alcohol.
29 arcted segment is often akinetic rather than dyskinetic because early reperfusion prevents transmural
30 artial alleviation of motor deficits and LID dyskinetic behavior, revealing an unexpected prokinetic
31 riatonigral medium spiny neurons exacerbated dyskinetic behavior, whereas overexpression of cJun, whi
32 and cocaine-induced locomotion and abolished dyskinetic behaviors in response to the Parkinson's dise
33                     Tat-D2Ri also alleviated dyskinetic behaviors induced by levodopa.
34 ndrites that appear to be directly linked to dyskinetic behaviors, since they were not seen in the st
35 ic target for use in preventing or reversing dyskinetic behaviors.
36 irectionally and found them able to modulate dyskinetic behaviors.
37 ABA efflux, coincident with the emergence of dyskinetic behaviors.
38  dSPNs, enabled LTP reversal, and attenuated dyskinetic behaviors.
39 sensitive molecular response associated with dyskinetic behaviors.
40 e and motor performance were evident only in dyskinetic, but not in non-dyskinetic, rats.
41 uced striatal and thalamic opioid binding in dyskinetic, but not in nondyskinetic, PD patients.
42 ause is absent in parkinsonian mice rendered dyskinetic by chronic L-DOPA treatment but can be reinst
43                                              Dyskinetic cerebral palsy (DCP) is the second most commo
44                         Patients with severe dyskinetic cerebral palsy (Gross Motor Functioning Class
45    Here, we report a subject presenting with dyskinetic cerebral palsy and partial agenesis of the co
46  on individual goals in patients with severe dyskinetic cerebral palsy.
47 ving treatment goals in patients with severe dyskinetic cerebral palsy.
48 reatment of dystonia in patients with severe dyskinetic cerebral palsy; however, the current level of
49 normal airway epithelial cells had stiff and dyskinetic cilia beating patterns compared to control ce
50 y transmission electron microscopy, but with dyskinetic cilia beating.
51 at NMDA receptor blockade may ameliorate the dyskinetic complications of long-term levodopa therapy,
52 w, and comprised all infants with spastic or dyskinetic CP not caused by developmental abnormalities
53  children with moderate to severe spastic or dyskinetic CP not due to postnatal brain injury or devel
54 ral globus pallidus injury in the setting of dyskinetic CP.
55                Whereas DMI alone elicited no dyskinetic effects in lesioned rats, DMI + L-DOPA-treate
56 fficult to separate the antiparkinsonian and dyskinetic effects of levodopa.
57 or function was obtained without any adverse dyskinetic effects.
58  developmental and/or degenerative epileptic-dyskinetic encephalopathy to childhood-onset neurodegene
59 uum ranging from developmental and epileptic-dyskinetic encephalopathy to variable neurodevelopmental
60 , chemogenetic inhibition of iMSNs triggered dyskinetic episodes in PNKD mice.
61                  Segmental shortening in the dyskinetic ischemic region improved only minimally at th
62                               Dyskinesia and dyskinetic-like movements are more common in subjects wi
63                   Spectrum subjects had more dyskinetic-like movements than normal subjects.
64 bjects with schizotypal personality had more dyskinetic-like movements than subjects with schizoid pe
65                                              Dyskinetic-like movements were assessed in 34 spectrum s
66         They also tested the hypothesis that dyskinetic-like movements would increase after repeated
67  of behavioral sensitization (an increase in dyskinetic-like movements), but spectrum subjects showed
68  subjects showed an abnormal response (fewer dyskinetic-like movements).
69 -4-phenyl-1,2,3,6-tetrahydropyridine-treated dyskinetic macaques without affecting the global parkins
70 Kv1 channels, which are tonically blocked in dyskinetic mice by a mechanism depending on D5R ligand-i
71 onal corticostriatal connectivity of SPNs in dyskinetic mice oscillate between LID on- and off-states
72 this normalization of basal excitability, in dyskinetic mice, the selective D1R agonist SKF38393 incr
73 nd sumanirole failed to reinstate a pause in dyskinetic mice.
74 Hb was found to be metabolically modified in dyskinetic monkeys and its neuronal firing frequency sig
75 , to test the effect of grafts on previously dyskinetic monkeys.
76  in ciliary loss, reduced beat frequency and dyskinetic motion of the remaining ventral cilia.
77 e, consisting of transient attacks of severe dyskinetic motor behavior.
78 on within this network may contribute to the dyskinetic motor spasms.
79 ent displaying a disorder characterized by a dyskinetic movement disorder, developmental delay, and a
80 g this variant presented with an early onset dyskinetic movement disorder, severe motor delay, and pr
81                                              Dyskinetic movement scores correlated with positive symp
82 ity, seizures of different types, tremor and dyskinetic movements and, in some cases, death in early
83 kinesia, as seen in Parkinson's disease, and dyskinetic movements as seen in Huntington's disease or
84 or cortex does not directly trigger specific dyskinetic movements during LID but, instead, dysregulat
85  neurocircuitry hypothesized to give rise to dyskinetic movements has also been implicated in psychot
86  and signaling and alleviates L-DOPA-induced dyskinetic movements in pituitary homeobox 3 (Pitx3)-def
87 ine and l-dopa-induced normal ambulatory and dyskinetic movements in Pitx3 mutant mice, whereas the s
88 f which cells and patterns of activity cause dyskinetic movements might inform the development of new
89 eatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical an
90 ggested to underlie dopamine-agonist-induced dyskinetic movements that develop during the treatment o
91 nown about the relationships between ongoing dyskinetic movements, gamma and neuronal activity at fas
92 e of neural networks to suppress involuntary dyskinetic movements.
93  dorsal striatum may enhance both normal and dyskinetic movements.
94  dopamine agonist drugs are able to initiate dyskinetic movements.
95 euronal communication, with the emergence of dyskinetic movements.
96         Most hypokinetic and 40% of akinetic/dyskinetic myocardial segments contained scintigraphical
97 oxysmal episodes in puberty, either dystonic/dyskinetic or "shivering" attacks, triggered by stretchi
98           All monitored segments were either dyskinetic or akinetic during the 30-minute occlusion.
99  of left ventricular (LV) reconstruction for dyskinetic or akinetic LV segments in patients with isch
100  or bilateral spasticity, as in those with a dyskinetic or ataxic disability.
101 ography was performed in the 'ON' condition, dyskinetic patients had higher (11)C-CNS 5161 uptake in
102  withdrawn from levodopa, dyskinetic and non-dyskinetic patients had similar levels of tracer uptake
103 atients without dyskinesias, suggesting that dyskinetic patients may have abnormal glutamatergic tran
104            The role of glutamate function in dyskinetic patients with Parkinson's disease, however, i
105 ed prefrontal opioid receptor binding in the dyskinetic patients.
106 ether the opioid system is involved in human dyskinetic PD, we measured in vivo opioid receptor bindi
107 fidence in the Cebus model as a predictor of dyskinetic potential.
108          These data further support the anti-dyskinetic properties of ketamine and suggest that ketam
109 e for a dramatic rewiring of the striatum of dyskinetic rats and that this rewiring involves corticos
110 s overexpressed only on the lesioned side of dyskinetic rats in LHb and co-localized with DeltaFosB,
111 Ns; both phenomena mimicking changes seen in dyskinetic rats.
112 ession of FosB, ARC, Zif268 and FRA2 only in dyskinetic rats.
113 nd Nurr1 agonism exacerbated LID severity in dyskinetic rats.
114 e evident only in dyskinetic, but not in non-dyskinetic, rats.
115 ration response, long-duration response, and dyskinetic response to levodopa change during long-term
116 y raise the possibility that the maladaptive dyskinetic responses to chronic l-DOPA treatment in Park
117 PNs oppositely modulate both therapeutic and dyskinetic responses to dopamine replacement therapy in
118 mice, hM3Dq stimulation of dSPNs exacerbated dyskinetic responses to L-DOPA, while stimulation of iSP
119 of 360 segments), especially in akinetic and dyskinetic segments (276 [91%] of 303), irrespective of
120 , with akinetic segments counting double and dyskinetic segments counting triple.
121 mber by excluding scar in either akinetic or dyskinetic segments.
122 ent the appearance of motor fluctuations and dyskinetic side effects associated with standard oral do
123 larly the motor fluctuations and troublesome dyskinetic side effects.
124 A on the therapeutic parameters, but develop dyskinetic side effects.
125 l motor sensitization, but also develop less dyskinetic side effects.
126 nd might not be associated with debilitating dyskinetic side-effects after prolonged treatment.
127 ith drug effects, lead to the development of dyskinetic signs.
128                       Microtubule sliding of dyskinetic sperm from Cfap45(-/-) mice is rescued with t
129 and ataxic) more often had high myopia, CVI, dyskinetic strabismus, and gaze dysfunction.
130 or high myopia, absence of binocular fusion, dyskinetic strabismus, severe gaze dysfunction, and opti
131                                Patients with dyskinetic symptoms at baseline experienced significant
132 ine antagonist onto the cortical surface the dyskinetic symptoms disappear.
133 ioning that might underlie the generation of dyskinetic symptoms in patients with PD who have receive
134                       Some of the hereditary dyskinetic syndromes are characterized by paroxysmal ons
135 l-genetic spectrum of combined epileptic and dyskinetic syndromes.
136 ach group) aged 12 to 59 months with spastic/dyskinetic UCP and able to follow instructions were need
137 pectively, in segments that were akinetic or dyskinetic under resting conditions (83% concordance wit
138        Considering dibenzazepines, 2 was not dyskinetic whereas 2a was dyskinetic.
139  6-hydroxydopamine lesions (6-OHDA) rendered dyskinetic with chronic L-DOPA treatment reveals a compl
140 phenyl-1,2,3,6-tetrahydropyridine (MPTP) and dyskinetic with levodopa.

 
Page Top